KRAS and non-small cell lung carcinoma: In a study on the clinical efficacy of chemotherapeutic agents in patients with advanced NSCLC with KRAS mutations, platinum-based chemotherapy with taxane had the best ORR, especially when used in combination with bevacizumab.